This report was first published by Endpoints News. To see the original version, click here
A man in his early 80s who was recently hospitalized with liver injury a few weeks after receiving an experimental gene editing therapy died on Wednesday night.
Intellia Therapeutics reported the death in its third quarter earnings on Thursday afternoon. The company’s stock fell as much as 27% in after hours trading.
您已閱讀21%（407字），剩余79%（1522字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。